Skip to main navigationSkip to main content
The University of Southampton
Southampton Health Technology Assessments Centre

Asthma

Click on the title for more information (where available).

Cooper, Keith, Frampton, Geoff, Harris, Petra, Rose, Micah, Chorozoglou, Maria and Pickett, Karen (2018) Reslizumab for treating asthma with elevated blood eosinophils inadequately controlled by inhaled corticosteroids: An evidence review group perspective of a NICE single technology appraisal. PharmacoEconomics, 36 (5), 545-553

Cooper, K., Harris, P., Rose, M., Chorozoglou, M., Pickett, K., & Frampton, G. Reslizumab for treating asthma with elevated blood eosinophils inadequately controlled by inhaled corticosteroids. NIHR Journals Library (2017)

Frampton GK, Shepherd J. Patient-reported outcomes in clinical trials of inhaled asthma medications: systematic review and research needs. Quality of Life Research 2011;20(3):343-57.

Jones J, Shepherd J, Hartwell D, Harris P, Cooper K, Takeda A et al. Omalizumab for the treatment of severe persistent allergic asthma. Health Technology Assessment 2009;13(Suppl 2):31-9.  

Main C, Shepherd J, Anderson R, Rogers G, Thompson-Coon J, Lui Z et al. Inhaled corticosteroids and Long Acting Beta-2 Agonists for the treatment of chronic asthma in children under the age of 12 years: Systematic review and economic analysis. Health Technology Assessment 2008;12(20).

Shepherd J, Rogers G, Anderson R, Main C, Thompson-Coon J, Hartwell D et al. Inhaled corticosteroids and Long Acting Beta-2 Agonists for the treatment of chronic asthma in adults and children aged 12 years and over: systematic review and economic analysis. Health Technology Assessment 2008;12(9).  

Privacy Settings